Search Results - "Kamar, N."

Distinct modes of TNF signaling through its two receptors in health and disease by Atretkhany, Kamar‐Sulu N., Gogoleva, Violetta S., Drutskaya, Marina S., Nedospasov, Sergei A.

“…TNF is a key proinflammatory and immunoregulatory cytokine whose deregulation is associated with the development of autoimmune diseases and other pathologies…”
Get full text

Efficacy and Safety of Sofosbuvir‐Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation by Kamar, N., Marion, O., Rostaing, L., Cointault, O., Ribes, D., Lavayssière, L., Esposito, L., Del Bello, A., Métivier, S., Barange, K., Izopet, J., Alric, L.

“…There is no approved therapy for hepatitis C virus (HCV) infection after kidney transplantation, and no data regarding the use of new‐generation direct…”
Get full text

Lymphotoxins from distinct types of lymphoid cells differentially contribute to neuroinflammation by Gogoleva, Violetta S., Drutskaya, Marina S., Vorontsov, Alexander I., Atretkhany, Kamar‐Sulu N., Belogurov, Alexey A., Kruglov, Andrey A., Nedospasov, Sergei A.

“…Lymphotoxin α and lymphotoxin β (LTs), TNF superfamily members, are expressed in either soluble (LTα3) or membrane‐bound (LTα1β2 or LTα2β1) forms. In the…”
Get full text

Reduction of Extended‐Release Tacrolimus Dose in Low‐Immunological‐Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor‐Specific Antibodies: A Randomized Study by Gatault, P., Kamar, N., Büchler, M., Colosio, C., Bertrand, D., Durrbach, A., Albano, L., Rivalan, J., Le Meur, Y., Essig, M., Bouvier, N., Legendre, C., Moulin, B., Heng, A.‐E., Weestel, P.‐F., Sayegh, J., Charpentier, B., Rostaing, L., Thervet, E., Lebranchu, Y.

“…The aim of this study (ClinicalTrials.gov, NCT01744470) was to determine the efficacy and safety of two different doses of extended‐release tacrolimus (TacER)…”
Get full text

How Should Hepatitis E Virus Infection Be Defined in Organ‐Transplant Recipients? by Kamar, N., Rostaing, L., Legrand‐Abravanel, F., Izopet, J.

Get full text

Intrinsic TNFR2 signaling in T regulatory cells provides protection in CNS autoimmunity by Atretkhany, Kamar-Sulu N., Mufazalov, Ilgiz A., Dunst, Josefine, Kuchmiy, Anna, Gogoleva, Violetta S., Andruszewski, David, Drutskaya, Marina S., Faustman, Denise L., Schwabenland, Marius, Prinz, Marco, Kruglov, Andrey A., Waisman, Ari, Nedospasov, Sergei A.

“…TNF is a multifunctional cytokine involved in autoimmune disease pathogenesis that exerts its effects through two distinct TNF receptors, TNFR1 and TNFR2…”
Get full text

In vitro evaluation of cytotoxicity and genotoxicity of porous nickel titanium dental implants produced by metal injection molding technique by N W N A, Mustafa, R, Ahmad, N H, Kamar Affendi, E, Sulaiman, M A A, Khushaini, M H, Ismail, L K, Teh, M Z, Salleh

“…Porous NiTi (pNiTi) is a promising biomaterial for functional long‐term implantation that has been produced using various manufacturing techniques and tested…”
Get full text

Three‐Year Outcomes From BENEFIT‐EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys by Medina Pestana, J. O., Grinyo, J. M., Vanrenterghem, Y., Becker, T., Campistol, J. M., Florman, S., Garcia, V. D., Kamar, N., Lang, P., Manfro, R. C., Massari, P., Rial, M. D. C., Schnitzler, M. A., Vitko, S., Duan, T., Block, A., Harler, M. B., Durrbach, A.

“…Recipients of extended‐criteria donor (ECD) kidneys have poorer long‐term outcomes compared to standard‐criteria donor kidney recipients. We report 3‐year…”
Get full text

Complement Genes Strongly Predict Recurrence and Graft Outcome in Adult Renal Transplant Recipients with Atypical Hemolytic and Uremic Syndrome by Le Quintrec, M., Zuber, J., Moulin, B., Kamar, N., Jablonski, M., Lionet, A., Chatelet, V., Mousson, C., Mourad, G., Bridoux, F., Cassuto, E., Loirat, C., Rondeau, E., Delahousse, M., Frémeaux‐Bacchi, V.

“…Atypical hemolytic and uremic syndrome (aHUS) is a severe disease strongly associated with genetic abnormalities in the complement alternative pathway. In…”
Get full text

Prevalence, Incidence and Risk Factors for Donor‐Specific Anti‐HLA Antibodies in Maintenance Liver Transplant Patients by Del Bello, A., Congy‐Jolivet, N., Muscari, F., Lavayssière, L., Esposito, L., Cardeau‐Desangles, I., Guitard, J., Dörr, G., Suc, B., Duffas, J. P., Alric, L., Bureau, C., Danjoux, M., Guilbeau‐Frugier, C., Blancher, A., Rostaing, L., Kamar, N.

“…Although large retrospective studies have identified the presence of donor‐specific antibodies (DSAs) to be a risk factor for rejection and impaired survival…”
Get full text

Protracted Fecal Shedding of HEV During Ribavirin Therapy Predicts Treatment Relapse by Abravanel, Florence, Lhomme, Sébastien, Rostaing, Lionel, Kamar, Nassim, Izopet, Jacques

“…Twenty-four solid-organ-transplant recipients with chronic hepatitis E virus (HEV) infections were given ribavirin therapy for 3 months. All the patients with…”
Get full text

Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study by Uhlin, Fredrik, Szpirt, Wladimir, Kronbichler, Andreas, Bruchfeld, Annette, Soveri, Inga, Rostaing, Lionel, Daugas, Eric, Lionet, Arnaud, Kamar, Nassim, Rafat, Cédric, Mysliveček, Marek, Tesař, Vladimír, Fernström, Anders, Kjellman, Christian, Elfving, Charlotte, McAdoo, Stephen, Mölne, Johan, Bajema, Ingeborg, Sonesson, Elisabeth, Segelmark, Mårten

“…The prognosis for kidney survival is poor in patients presenting with circulating anti-glomerular basement membrane (GBM) antibodies and severe kidney injury…”
Get full text

Risk Factors of Pneumocystis Pneumonia in Solid Organ Recipients in the Era of the Common Use of Posttransplantation Prophylaxis by Iriart, X., Challan Belval, T., Fillaux, J., Esposito, L., Lavergne, R.‐A., Cardeau‐Desangles, I., Roques, O., Del Bello, A., Cointault, O., Lavayssière, L., Chauvin, P., Menard, S., Magnaval, J.‐F., Cassaing, S., Rostaing, L., Kamar, N., Berry, A.

“…Pneumocystis pneumonia (PCP) in solid organ transplant (SOT) recipients becomes rare in the immediate posttransplantation period thanks to generalized…”
Get full text

Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial by Saliba, F., Duvoux, C., Gugenheim, J., Kamar, N., Dharancy, S., Salamé, E., Neau‐Cransac, M., Durand, F., Houssel‐Debry, P., Vanlemmens, C., Pageaux, G., Hardwigsen, J., Eyraud, D., Calmus, Y., Di Giambattista, F., Dumortier, J., Conti, F.

“…SIMCER was a 6‐mo, multicenter, open‐label trial. Selected de novo liver transplant recipients were randomized (week 4) to everolimus with low‐exposure…”
Get full text

Neurologic Disorders in Immunocompetent Patients with Autochthonous Acute Hepatitis E by Perrin, H Blasco, Cintas, P, Abravanel, F, Gérolami, R, d'Alteroche, L, Raynal, J-N, Alric, L, Dupuis, E, Prudhomme, L, Vaucher, E, Couzigou, P, Liversain, J-M, Bureau, C, Vinel, J-P, Kamar, N, Izopet, J, Peron, J-M

“…Neurologic disorders, mainly Guillain-Barré syndrome and Parsonage–Turner syndrome (PTS), have been described in patients with hepatitis E virus (HEV)…”
Get full text

Acute autochthonous hepatitis E in western patients with underlying chronic liver disease: A role for ribavirin? by Péron, J.M, Dalton, H, Izopet, J, Kamar, N

Get full text

Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD‐REIN cohort by Laville, Solène M., Metzger, Marie, Stengel, Bénédicte, Jacquelinet, Christian, Combe, Christian, Fouque, Denis, Laville, Maurice, Frimat, Luc, Ayav, Carole, Speyer, Elodie, Robinson, Bruce M., Massy, Ziad A., Liabeuf, Sophie, Hannedouche, T., Moulin, B., Klein, A., Combe, C., Bourdenx, J.P., Keller, A., Delclaux, C., Vendrely, B., Deroure, B., Lacraz, A., Lobbedez, T., Landru, I., Massy, Z., Lang, P., Belenfant, X., Thervet, E., Urena, P., Delahousse, M., Vela, C., Essig, M., Sekhri, H., Smati, M., Jamali, M., Hacq, B., Panescu, V., Bellou, M., Frimat, Luc, Kamar, N., Noël, C., Glowacki, F., Maisonneuve, N., Azar, R., Hoffmann, M., Hourmant, M., Testa, A., Besnier, D., Choukroun, G., Lambrey, G., Burtey, S., Lebrun, G., Magnant, E., Laville, M., Fouque, D., Juillard, L., Chazot, C., Zaoui, P., Kuentz, F.

“…Aims Drug prescription is difficult to manage in patients with chronic kidney disease (CKD). We assessed the prevalence and determinants of inappropriate drug…”
Get full text

T cell reconstitution after lymphocyte depletion features a different pattern of inhibitory receptor expression in ABO‐ versus HLA‐incompatible kidney transplant recipients by Del Bello, A., Kamar, N., Treiner, E.

“…Summary Chronic antigen stimulation can lead to immune exhaustion (a state of T cell dysfunction). Several phenotypical signatures of T cell exhaustion have…”
Get full text

Incidence and Predictive Factors for Infectious Disease after Rituximab Therapy in Kidney‐Transplant Patients by Kamar, N., Milioto, O., Puissant‐Lubrano, B., Esposito, L., Pierre, M. C., Mohamed, A. Ould, Lavayssière, L., Cointault, O., Ribes, D., Cardeau, I., Nogier, M. B., Durand, D., Abbal, M., Blancher, A., Rostaing, L.

“…Rituximab off‐label use includes organ transplantation. We review the occurrence of infectious disease and its outcome after rituximab therapy. Between April…”
Get full text

Impact of Early Blood Transfusion After Kidney Transplantation on the Incidence of Donor‐Specific Anti‐HLA Antibodies by Ferrandiz, I., Congy‐Jolivet, N., Del Bello, A., Debiol, B., Trébern‐Launay, K., Esposito, L., Milongo, D., Dörr, G., Rostaing, L., Kamar, N.

“…Little is known about the impact of posttransplant blood transfusion on the sensitization of anti‐HLA antibodies and the formation of donor‐specific antibodies…”
Get full text